2025
Systemic chemotherapy in patients with unresectable pseudomyxoma peritonei from low-grade appendiceal mucinous neoplasms: a case series
Vierra M, Morgan R, Ostowari A, Turaga K, Shergill A, Eng O. Systemic chemotherapy in patients with unresectable pseudomyxoma peritonei from low-grade appendiceal mucinous neoplasms: a case series. Journal Of Gastrointestinal Oncology 2025, 16: 757-765. PMCID: PMC12078827, DOI: 10.21037/jgo-24-440.Peer-Reviewed Original ResearchLow-grade appendiceal mucinous neoplasmProgression-free survivalSystemic chemotherapyAppendiceal mucinous neoplasmPseudomyxoma peritoneiCase seriesCarcinoembryonic antigenMucinous neoplasmsFolinic acidAnti-vascular endothelial growth factorMedian progression-free survivalCEA responseMetastatic peritoneal diseaseElevated carcinoembryonic antigenPeritoneal cancer indexMedian follow-upBenefit of chemotherapyResponse to chemotherapyCycles of chemotherapyOutcomes of patientsTreated 5 patientsUniversity of Chicago Medical CenterEndothelial growth factorUnresectable diseasePeritoneal diseaseMedical therapy and outcomes in REVIVED-BCIS2 and STICHES: an individual patient data analysis
Ryan M, Petrie M, Kontopantelis E, Dodd M, Tong G, Marquis-Gravel G, Docherty K, Clayton T, Lansky A, Mamas M, Rouleau J, Velazquez E, Perera D. Medical therapy and outcomes in REVIVED-BCIS2 and STICHES: an individual patient data analysis. European Heart Journal 2025, ehaf080. PMID: 40048661, DOI: 10.1093/eurheartj/ehaf080.Peer-Reviewed Original ResearchCoronary artery bypass graftingPercutaneous coronary interventionMedical therapyPrimary outcome eventFollow-upPrimary outcomePatients treated with coronary artery bypass graftingOutcome eventsIndividual patient data analysisCoronary artery bypass graft surgeryIschaemic left ventricular dysfunctionMedian follow-upMulticentre randomized trialLeft ventricular dysfunctionOutcomes of patientsBenefit of coronary artery bypass graftingCompleteness of follow-upArtery bypass graftingCoronary artery diseasePatient data analysisIschaemic cardiomyopathyVentricular dysfunctionSurgical treatmentHeart failurePooled analysisOutcomes of Mechanical Thrombectomy for Acute Limb Ischemia at a Tertiary Referral Center
Loh S, Nasir A, Strosberg D, Ochoa Chaar C, Guzman R, Tonnessen B. Outcomes of Mechanical Thrombectomy for Acute Limb Ischemia at a Tertiary Referral Center. Journal Of Vascular Surgery 2025 PMID: 40024380, DOI: 10.1016/j.jvs.2025.02.027.Peer-Reviewed Original ResearchTertiary referral centerAcute limb ischemiaAdverse cardiovascular eventsReferral centerMechanical thrombectomyOpen surgeryThirty-dayCardiovascular eventsConversion to open surgeryLimb ischemiaTreated with mechanical thrombectomyMedian follow-upCatheter-directed thrombolysisManagement of acute limb ischemiaDuration of symptomsThirty-day complicationsOutcomes of mechanical thrombectomyRisk of limb lossHigh risk of limb lossAcute limb ischemia casesMechanical thrombectomy devicesBleeding eventsMulticenter trialThrombosed bypassesThrombosed stentSignificance of Coronary Artery Calcifications and Ischemic Electrocardiographic Changes Among Patients Undergoing Myocardial Perfusion Imaging
Kokkinidis D, Kyriakoulis I, Chui P, Agarwal R, Liu Y, Khera R, Sinusas A, Velazquez E, Miller E, Feher A. Significance of Coronary Artery Calcifications and Ischemic Electrocardiographic Changes Among Patients Undergoing Myocardial Perfusion Imaging. JACC Advances 2025, 4: 101618. PMID: 39983619, PMCID: PMC11891677, DOI: 10.1016/j.jacadv.2025.101618.Peer-Reviewed Original ResearchCoronary artery calcificationMyocardial perfusion imagingIschemic ECG changesLow event ratesECG changesNormal perfusionArtery calcificationPerfusion imagingSingle-photon emission computed tomography/computed tomographyStress ECGCAC evaluationPresence of coronary artery calcificationSuspected coronary artery diseaseMedian follow-upEvent ratesIschemic electrocardiographic changesAnalysis to patientsComposite endpoint rateCoronary artery diseaseTomography/computed tomographyPrognostic informationMACE rateFollow-upSubgroup analysisAdverse outcomesCabozantinib (cabo) and nivolumab (nivo) with or without CBM588 in patients with metastatic renal cell carcinoma: Updated clinical outcomes of a phase I study.
Ebrahimi H, Meza L, Dizman N, Barragan-Carrillo R, Li X, Llamas-Quitiquit M, Hsu J, Zengin Z, Castro D, Mercier B, Zugman M, Jaime-Casas S, Chehrazi-Raffle A, Trent J, Lee P, Takahashi M, Dorff T, Caporaso G, Lee K, Pal S. Cabozantinib (cabo) and nivolumab (nivo) with or without CBM588 in patients with metastatic renal cell carcinoma: Updated clinical outcomes of a phase I study. Journal Of Clinical Oncology 2025, 43: 543-543. DOI: 10.1200/jco.2025.43.5_suppl.543.Peer-Reviewed Original ResearchProgression-free survivalTreatment-related adverse eventsClinical benefitControl armTreatment armsFollow-upImproving progression-free survivalMedian progression-free survivalMetastatic renal cell carcinomaTime of data cutoffTarget lesion sizeTreatment naive patientsMedian follow-upPhase I studyKaplan-Meier methodSecondary clinical endpointsRenal cell carcinomaKarnofsky performance statusFisher's exact testMedian OSSarcomatoid featuresStable diseaseComplete responseData cutoffPapillary histologyAvelumab first-line maintenance (1LM) in patients (pts) with advanced urothelial carcinoma (aUC) with or without diabetes mellitus (DM): Long-term outcomes from JAVELIN Bladder 100.
Gupta S, Grivas P, Park S, Petrylak D, Tyroller K, Hoffman J, Bellmunt J. Avelumab first-line maintenance (1LM) in patients (pts) with advanced urothelial carcinoma (aUC) with or without diabetes mellitus (DM): Long-term outcomes from JAVELIN Bladder 100. Journal Of Clinical Oncology 2025, 43: 869-869. DOI: 10.1200/jco.2025.43.5_suppl.869.Peer-Reviewed Original ResearchProgression-free survivalAdvanced urothelial carcinomaBest supportive carePlatinum-based chemotherapyOverall survivalDiabetes mellitusAdverse eventsAssociated with long-term efficacyImmune-related adverse eventsTreatment-related adverse eventsFirst-line maintenanceAssociated with reduced efficacyEfficacy of immunotherapyMedian follow-upProlonged overall survivalLong-term efficacyPresence of DMLong-term outcomesPost hoc exploratory analysisJAVELIN BladderMedian OSMetastatic UCUrothelial carcinomaEligible ptsPrimary endpointDatopotamab deruxtecan (Dato-DXd) in locally advanced/metastatic urothelial cancer: Updated results from the phase 1 TROPIONPanTumor01 study.
Meric-Bernstam F, Alhalabi O, Lisberg A, Drakaki A, Garmezy B, Kogawa T, Spira A, Salkeni M, Gao X, Tolcher A, Bhave M, Doroshow D, Hoffman-Censits J, Klauss G, Kaga Y, Kakurai Y, Kojima T. Datopotamab deruxtecan (Dato-DXd) in locally advanced/metastatic urothelial cancer: Updated results from the phase 1 TROPIONPanTumor01 study. Journal Of Clinical Oncology 2025, 43: 663-663. DOI: 10.1200/jco.2025.43.5_suppl.663.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsBlinded independent central reviewProgression-free survivalDuration of responsePartial responseIndependent central reviewComplete responseConfirmed ORRUrothelial cancerCentral reviewMedian duration of responseMedian progression-free survivalResponse rateImmune checkpoint inhibitorsInterstitial lung disease/pneumonitisTreatment-related AEsMedian follow-upSolid tumor typesAntibody-drug conjugatesPrimary study objectiveCheckpoint inhibitorsDose interruptionPretreated ptsStable diseaseData cutoffDeterminants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
Cortellini A, Brunetti L, Di Fazio G, Garbo E, Pinato D, Naidoo J, Katz A, Loza M, Neal J, Genova C, Gettinger S, Kim S, Jayakrishnan R, Zarif T, Russano M, Pecci F, Di Federico A, Awad M, Alessi J, Montrone M, Owen D, Signorelli D, Fidler M, Li M, Camerini A, De Giglio A, Young L, Vincenzi B, Metro G, Passiglia F, Yendamuri S, Guida A, Ghidini M, Awosika N, Napolitano A, Fulgenzi C, Grisanti S, Grossi F, D’Incecco A, Josephides E, Van Hemelrijck M, Russo A, Gelibter A, Spinelli G, Verrico M, Tomasik B, Giusti R, Newsom-Davis T, Bria E, Sebastian M, Rost M, Forster M, Mukherjee U, Landi L, Mazzoni F, Aujayeb A, Dupont M, Curioni-Fontecedro A, Chiari R, Pantano F, Morabito A, Leonetti A, Friedlaender A, Addeo A, Zoratto F, De Tursi M, Cantini L, Roca E, Mountzios G, Della Gravara L, Kalvapudi S, Inno A, Bironzo P, Di Marco Barros R, O’Reilly D, Bell J, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Majem M, Agustoni F, Cortinovis D, Tonini G, Minuti G, Bennati C, Mezquita L, Gorría T, Servetto A, Beninato T, Russo G, Rogado J, Moliner L, Biello F, Nana F, Dingemans A, Aerts J, Ferrara R, Torri V, Abu Hejleh T, Takada K, Naqash A, Garassino M, Peters S, Wakelee H, Nassar A, Ricciuti B. Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. Journal For ImmunoTherapy Of Cancer 2025, 13: e010674. PMID: 39904562, PMCID: PMC11795382, DOI: 10.1136/jitc-2024-010674.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerAdvanced non-small cell lung cancerProgrammed cell death ligand 1Eastern Cooperative Oncology Group performance statusData cut-offLong-term efficacyIndividual patient-level dataMedian OSPembrolizumab monotherapySurvival rateProgressive diseaseDiscontinued treatment due to progressive diseaseTreated with first-line pembrolizumabClinical trialsPredictors of 5-year survivalFirst-line pembrolizumab monotherapyCell death ligand 1Pre-existing autoimmune diseaseFirst-line pembrolizumabKEYNOTE-024 trialPD-L1 TPSPermanently discontinue treatmentDeath-ligand 1Efficacy of pembrolizumabMedian follow-upOutcomes after Allogeneic Transplantation with Reduced Intensity Conditioning and Post Transplant Cyclophosphamide GvHD Prophylaxis in T-Cell Lymphomas: A Single Institution Experience
Taborda C, Isufi I, Bar N, Sethi T, Gowda L, Perreault S, Roberts K, Seropian S, Foss F. Outcomes after Allogeneic Transplantation with Reduced Intensity Conditioning and Post Transplant Cyclophosphamide GvHD Prophylaxis in T-Cell Lymphomas: A Single Institution Experience. Transplantation And Cellular Therapy 2025, 31: s393-s394. DOI: 10.1016/j.jtct.2025.01.606.Peer-Reviewed Original ResearchAcute graft-versus-host diseaseReduced-intensity conditioningGraft-versus-lymphomaNon-relapse mortalityPosttransplant cyclophosphamideT-cell lymphomaAllo-SCTOverall survivalGVHD prophylaxisT cellsAssociated with improved overall survivalTacrolimus-based GVHD prophylaxisAllogeneic stem cell transplantationGraft-versus-host diseaseAggressive T-cell lymphomaT-cell lymphoma patientsHaplo-identical transplantationReduced intensity conditioningImproved overall survivalRelapse-free survivalMedian follow-upSingle-center experienceReduce treatment toxicityStem cell transplantationSingle institution experienceLong-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial
Bar N, Mina R, Mylin A, Yokoyama H, Magen H, Alsdorf W, Minnema M, Shune L, Isufi I, Harrison S, Shah U, De Champlain A, Gries K, Chen D, Li Q, Yeh T, Slaughter A, Lonardi C, Benachour N, Ghosh A, Deraedt W, Vogel M, Lendvai N, Patel N, Filho O, Florendo E, Karlin L, Weisel K. Long-Term Benefits in Patient-Reported Outcomes and Time to Next Anti-Myeloma Therapy of Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care for Patients with Lenalidomide-Refractory Multiple Myeloma: Results from the Phase 3 Cartitude-4 Clinical Trial. Transplantation And Cellular Therapy 2025, 31: s404-s405. DOI: 10.1016/j.jtct.2025.01.623.Peer-Reviewed Original ResearchAnti-myeloma therapyLenalidomide-refractory multiple myelomaMedian follow-upCilta-celProgressive diseaseMultiple myelomaStandard of careFollow-upCiltacabtagene autoleucelProgression-free survivalYears of follow-upKaplan-Meier methodCox proportional hazards modelsWorsening of symptomsProportional hazards modelPatient-reported outcomesEuropean Organization for ResearchOverall survivalProlonged survivalImmunomodulatory agentsSOC armGlobal health status/quality of lifeAnchor-based approachClinical trialsLong-term benefitsEndovascular Repair vs Medical Therapy for Uncomplicated Acute Type B Dissection: Aortic Remodeling
Higaki A, Hameed I, Erez E, Hu K, Asmelash S, Chatterjee D, Shou B, Zafar M, Assi R, Vallabhajosyula P. Endovascular Repair vs Medical Therapy for Uncomplicated Acute Type B Dissection: Aortic Remodeling. Annals Of Thoracic Surgery Short Reports 2025 DOI: 10.1016/j.atssr.2025.01.012.Peer-Reviewed Original ResearchUncomplicated acute type B aortic dissectionThoracic endovascular aortic repairOptimal medical therapyMedical therapyAortic remodelingAortic levelsClinical outcomesClinical outcomes of thoracic endovascular aortic repairLumen diameterPatients treated with thoracic endovascular aortic repairOutcomes of thoracic endovascular aortic repairUncomplicated acute type B dissectionAcute type B aortic dissectionOMT patientsAcute type B dissectionType B aortic dissectionFavorable aortic remodelingOptimal initial managementInitial treatment modalityMedian follow-upType B dissectionEndovascular aortic repairB aortic dissectionFalse lumen thrombosisLeft subclavian arteryRespiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study
Bajema K, Yan L, Li Y, Argraves S, Rajeevan N, Fox A, Vergun R, Berry K, Bui D, Huang Y, Lin H, Hynes D, Lucero-Obusan C, Schirmer P, Cunningham F, Huang G, Aslan M, Ioannou G. Respiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study. The Lancet Infectious Diseases 2025 PMID: 39848264, DOI: 10.1016/s1473-3099(24)00796-5.Peer-Reviewed Original ResearchRespiratory syncytial virusRespiratory syncytial virus vaccinePositive RSV testVaccine effectivenessRSV testCare encountersSecondary outcomesEmergency departmentRSV-associated hospitalisationsMedian follow-upUS Food and Drug AdministrationHealth-care useVeterans Health AdministrationRespiratory illness seasonMatched index dateElectronic health recordsLower respiratory tract diseaseRSV-related illnessFood and Drug AdministrationDepartment of Veterans Affairs Cooperative Studies ProgramVeterans Affairs Cooperative Studies ProgramCooperative Studies ProgramRSV infectionMedian ageUS DepartmentTransarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
Kudo M, Ren Z, Guo Y, Han G, Lin H, Zheng J, Ogasawara S, Kim J, Zhao H, Li C, Madoff D, Ghobrial R, Kawaoka T, Gerolami R, Ikeda M, Kumada H, El-Khoueiry A, Vogel A, Peng X, Mody K, Dutcus C, Dubrovsky L, Siegel A, Finn R, Llovet J, investigators L. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. The Lancet 2025, 405: 203-215. PMID: 39798578, DOI: 10.1016/s0140-6736(24)02575-3.Peer-Reviewed Original ResearchConceptsEastern Cooperative Oncology GroupNon-metastatic hepatocellular carcinomaProgression-free survivalTreatment-related adverse eventsPembrolizumab groupPhase 3 studyTransarterial chemoembolisationPlacebo groupHepatocellular carcinomaIntention-to-treatOverall survivalDouble-blindPerformance statusAdverse eventsFollow-upEastern Cooperative Oncology Group performance statusChild-Pugh class A diseaseMedian progression-free survivalSolid Tumors version 1.1Blinded independent central reviewA-fetoprotein levelAlbumin-bilirubin gradeResponse Evaluation CriteriaAs-treated populationMedian follow-upOutcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])
DeMichele A, Dueck A, Hlauschek D, Martin M, Burstein H, Pfeiler G, Zdenkowski N, Wolff A, Bellet-Ezquerra M, Winer E, Balic M, Miller K, Colleoni M, Lake D, Rubovsky G, Cameron D, Balko J, Singer C, Nowecki Z, Iwata H, Wolmark N, Parraga K, Rugo H, Steger G, Traina T, Werutsky G, Czajkowska D, Metzger O, El-Abed S, Theall K, Lu R, O’Brien P, Fesl C, Mayer E, Gnant M. Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13]). Breast Cancer Research 2025, 27: 12. PMID: 39849600, PMCID: PMC11761723, DOI: 10.1186/s13058-024-01941-3.Peer-Reviewed Original ResearchConceptsLocoregional relapse-free survivalStandard adjuvant endocrine therapyYears of palbociclibAdjuvant endocrine therapyEndocrine therapyOverall survivalStage IIAPALLAS trialBreast cancerFollow-upBreast cancer-free survivalReducing breast cancer recurrenceStage IIA patientsHigher stage diseaseHormone-receptor-positiveRelapse-free survivalStage IIA diseaseYears of follow-upCancer-free survivalMedian follow-upPhase III trialsEarly breast cancerBreast cancer recurrenceBreast Cancer Study GroupNegative breast cancer
2024
Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma
Matei D, Enserro D, Randall M, Mutch D, Small W, DiSilvestro P, Spirtos N, O’Malley D, Cantuaria G, Michelin D, Waggoner S, Shahin M, Guntupalli S, Lara O, Ueland F, Warshal D, Bonebrake A, Tewari K, Tan A, Powell M, Walker J, Santin A, Kim J, Miller D. Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma. Journal Of Clinical Oncology 2024, 43: 1055-1060. PMID: 39700442, PMCID: PMC11908887, DOI: 10.1200/jco.24.01121.Peer-Reviewed Original ResearchConceptsRecurrence-free survivalRandomized phase III trialOverall survivalC-RTFederation of Gynecology and Obstetrics (FIGOInternational Federation of Gynecology and Obstetrics (FIGOFollow-upIncreased recurrence-free survivalLocally advanced endometrial cancerLocally advanced endometrial carcinomaRate of local recurrenceLymph-vascular space invasionLong-term follow-upGross residual diseaseStratified hazard ratioProbability of OSAdvanced endometrial cancerMedian follow-upAdvanced endometrial carcinomaKaplan-Meier methodPhase III trialsBody mass indexMedian OSOS benefitPositive cytologyType 2 diabetes genetic risk and incident diabetes across diabetes risk enhancers
Moura F, Kamanu F, Wiviott S, Giugliano R, Udler M, Florez J, Ellinor P, Sabatine M, Ruff C, Marston N. Type 2 diabetes genetic risk and incident diabetes across diabetes risk enhancers. Diabetes Obesity And Metabolism 2024, 27: 1287-1295. PMID: 39696834, DOI: 10.1111/dom.16123.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, Monoclonal, HumanizedAnticholesteremic AgentsCardiovascular DiseasesCholesterol, LDLDiabetes Mellitus, Type 2FemaleGenetic Predisposition to DiseaseGlycated HemoglobinHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIncidenceMaleMiddle AgedMultifactorial InheritancePCSK9 InhibitorsPolymorphism, Single NucleotideProprotein Convertase 9Risk FactorsConceptsT2D polygenic scoreBody mass indexProprotein convertase subtilisin/kexin type 9Incident diabetesPolygenic scoresGenetic riskIncident T2DHazard ratioStable atherosclerotic cardiovascular diseaseProprotein convertase subtilisin/kexin type 9 inhibitionYears of median follow-upFurther Cardiovascular Outcomes ResearchRisk factorsMean body mass indexCases of incident diabetesMedian follow-upLower body mass indexPredictor of incident diabetesEffects of evolocumabGenetic risk categoriesLDL cholesterol levelsT2D genetic riskDiabetes risk factorsType 2 diabetes genetic riskAtherosclerotic cardiovascular diseaseValidation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death.
Vutien P, Barnard Giustini A, Kim N, Moon A, Hsu C, Mezzacappa C, Borgerding J, Johnson K, VoPham T, Berry K, Beste L, Kaplan D, Taddei T, Ioannou G. Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death. Hepatology 2024 PMID: 39689352, DOI: 10.1097/hep.0000000000001183.Peer-Reviewed Original ResearchClinically significant portal hypertensionRisk of deathHepatic decompensationLiver stiffnessChronic liver diseasePlatelet countStratify risk of deathLiver diseaseRisk of hepatic decompensationMedian follow-upRisk of adverse outcomesSignificant portal hypertensionAssociated with risk of adverse outcomesRisk of decompensationAssociated with riskPortal hypertensionStratify riskFollow-upDecompensationAdverse outcomesCACLDPlatelet measuresPatientsPlateletDeathThe Relationship Between Quantitative Ischemia, Early Revascularization, and Major Adverse Cardiovascular Events A Multicenter Study
Miller R, Bednarski B, Cui Y, Calsavara V, Patel K, Rozanski A, Liang J, Builoff V, Acampa W, Bateman T, Di Carli M, Dorbala S, Einstein A, Fish M, Hauser M, Kaufmann P, Miller E, Ruddy T, Sharir T, Sinusas A, Dey D, Berman D, Slomka P. The Relationship Between Quantitative Ischemia, Early Revascularization, and Major Adverse Cardiovascular Events A Multicenter Study. JACC Advances 2024, 4: 101440. PMID: 39759439, PMCID: PMC11697767, DOI: 10.1016/j.jacadv.2024.101440.Peer-Reviewed Original ResearchMyocardial perfusion imagingEarly revascularizationMyocardial infarctionPerfusion imagingAssociated with reduced riskMedian follow-upImprove patient selectionAssociated with reduced deathSeverity of ischemiaMulticenter registryMale patientsPatient selectionRetrospective analysisFollow-upRandomized trialsRegistry sitesMyocardial ischemiaRevascularizationPatientsIschemiaSurvival analysisAuthors evaluated differencesPropensity scoreRegistryDeathMachine Learning-Based Prediction of Death and Hospitalization in Patients With Implantable Cardioverter Defibrillators
Rosman L, Lampert R, Wang K, Gehi A, Dziura J, Salmoirago-Blotcher E, Brandt C, Sears S, Burg M. Machine Learning-Based Prediction of Death and Hospitalization in Patients With Implantable Cardioverter Defibrillators. Journal Of The American College Of Cardiology 2024, 85: 42-55. PMID: 39570241, DOI: 10.1016/j.jacc.2024.09.006.Peer-Reviewed Original ResearchImplantable cardioverter-defibrillatorYear of device implantationAll-cause mortalityCardiac resynchronization therapyDeath/HF hospitalizationValidation cohortHeart failureDevice implantationTime of ICD implantationArea under the receiver-operating characteristic curveMedian follow-upReceiver-operating characteristic curvePredicting all-cause mortalityImplantable cardioverter-defibrillator patientsVeterans Health AdministrationPersonalized risk estimatesImplantable cardioverter defibrillatorResynchronization therapyBaseline demographicsICD implantationTraining cohortTrajectories of individual patientsProspective studyComposite outcomeContinuum of riskThe analytical and clinical validity of AI algorithms to score TILs in TNBC: can we use different machine learning models interchangeably?
Vidal J, Tsiknakis N, Staaf J, Bosch A, Ehinger A, Nimeus E, Salgado R, Bai Y, Rimm D, Hartman J, Acs B. The analytical and clinical validity of AI algorithms to score TILs in TNBC: can we use different machine learning models interchangeably? EClinicalMedicine 2024, 78: 102928. PMID: 39634035, PMCID: PMC11615110, DOI: 10.1016/j.eclinm.2024.102928.Peer-Reviewed Original ResearchTriple-negative breast cancerTumor-infiltrating lymphocytesBreast Cancer Research FoundationPrognostic validityMetastatic triple-negative breast cancerDisease-free survival endpointsHazard ratioHost anti-tumor immunityScored tumor infiltrating lymphocytesTumor-infiltrating lymphocyte scoresTriple-negative breast cancer patientsYears median follow-upTumour-infiltrating lymphocyte assessmentAnti-tumor immunityMedian follow-upIndependent prospective cohortTNBC tumorsPrognostic potentialProspective cohortBreast cancerPrognostic performanceAnalytic cohortFollow-upSchool of MedicineSwedish Society for Medical Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply